News >

Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial

Jason M. Broderick @jasoncology
Published: Thursday, May 10, 2018

Sandra Horning, MD

Sandra Horning, MD
Combination therapy with the PD-L1 inhibitor atezolizumab (Tecentriq) and the MEK inhibitor cobimetinib (Cotellic) failed to improve overall survival (OS) versus regorafenib (Stivarga) in previous treated patients with locally advanced or metastatic colorectal cancer (CRC), according to topline findings from the phase III IMblaze370 study.

wild-type, and the status of 2 patients was unknown. Sixty-six (79%) had received ≥5 previous systemic therapies.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication